Osteotropic cancers: From primary tumor to bone

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 177-193

  Buijs, Jeroen T ^a   van der Pluijm, Gabri ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone cancer; Bone metastasis; Breast cancer; Prostate cancer; Tumor progression

Indexed keywords

ANGIOGENESIS; BONE MATRIX; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; OSTEOCLAST; OSTEOLYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

BONE AND BONES; BONE MARROW; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; EPITHELIUM; HUMANS; MEDICAL ONCOLOGY; MESODERM; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 57349101056     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.044     Document Type: Review

References (218)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571-573
2. Coleman R.E., and Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55 (1987) 61-66
3. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
4. Galasko C. Incidence and Distribution of Skeletal Metastases, Skeletal Metastasis (1986), Butterworth, London pp. 14-21
5. Rubens R.D. The nature of metastatic bone disease. In: Rubens R.D., and Fogelman I. (Eds). Bone Metastases - Diagnosis and Treatment (1991), Springer-Verlag, London 1-10
6. Walther H.E. Krebsmetastase (1948), Beno Schwabe & Co, Basel
7. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007, CA. Cancer J. Clin. 57 (2007) 43-66
8. Chisholm G.D., Rana A., and Howard G.C. Management options for painful carcinoma of the prostate. Semin. Oncol. 20 (1993) 34-37
9. Berg A., Berner A., Lilleby W., Bruland O.S., Fossa S.D., Nesland J.M., and Kvalheim G. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int. J. Cancer 120 (2007) 1603-1609
10. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., and Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353 (2005) 793-802
11. Diel I.J., Kaufmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F., Kaul S., and Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88 (1996) 1652-1658
12. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 (1997) 1-18
13. Clines G.A., and Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 12 (2005) 549-583
14. Guise T.A., and Mundy G.R. Cancer and bone. Endocr. Rev. 19 (1998) 18-54
15. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 (2002) 584-593
16. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004) 1655-1664
17. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27 (2001) 165-176
18. Langley R.R., and Fidler I.J. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28 (2007) 297-321
19. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
20. Ronnov-Jessen L., Petersen O.W., and Bissell M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76 (1996) 69-125
21. Chung L.W., Baseman A., Assikis V., and Zhau H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol. 173 (2005) 10-20
22. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., and Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10 (1996) 2462-2477
23. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 8621-8623
24. Ellenrieder V., Hendler S.F., Boeck W., Seufferlein T., Menke A., Ruhland C., Adler G., and Gress T.M. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61 (2001) 4222-4228
25. Peinado H., Quintanilla M., and Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278 (2003) 21113-21123
26. Piek E., Moustakas A., Kurisaki A., Heldin C.H., and Ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J. Cell Sci. 112 (1999) 4557-4568
27. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002) 442-454
28. Valcourt U., Kowanetz M., Niimi H., Heldin C.H., and Moustakas A. TGF-{beta} and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16 (2005) 1987-2002
29. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66 (2006) 1883-1890
30. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
31. Dick J.E. Acute myeloid leukemia stem cells. Ann. N. Y. Acad. Sci. 1044 1-5 (2005) 1-5
32. Al Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
33. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007) 555-567
34. Miki J., Furusato B., Li H., Gu Y., Takahashi H., Egawa S., Sesterhenn I.A., McLeod D.G., Srivastava S., and Rhim J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 67 (2007) 3153-3161
35. Collins A.T., Berry P.A., Hyde C., Stower M.J., and Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65 (2005) 10946-10951
36. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
37. Tang D.G., Patrawala L., Calhoun T., Bhatia B., Choy G., Schneider-Broussard R., and Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinogen. 46 (2007) 1-14
38. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R.H., and Cote R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12 (2006) 5615-5621
39. Hill R.P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66 (2006) 1891-1895
40. Kumar R., and Fidler I.J. Angiogenic molecules and cancer metastasis. In Vivo 12 (1998) 27-34
41. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
42. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
43. Engels K., Fox S.B., Whitehouse R.M., Gatter K.C., and Harris A.L. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J. Pathol. 181 (1997) 207-212
44. Boudreau N., and Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5 (2003) 140-146
45. Heimann R., Ferguson D., Powers C., Recant W.M., Weichselbaum R.R., and Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J. Natl. Cancer Inst. 88 (1996) 1764-1769
46. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147 (1995) 9-19
47. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., and Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7 (2001) 575-583
48. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., and Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007) 463-475
49. van der Pluijm G., Lowik C., and Papapoulos S. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat. Rev. 26 (2000) 11-27
50. van der Pluijm G., Sijmons B., Vloedgraven H., Deckers M., Papapoulos S., and Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J. Bone Miner. Res. 16 (2001) 1077-1091
51. Mohammed R.A., Green A., El Shikh S., Paish E.C., Ellis I.O., and Martin S.G. Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br. J. Cancer 96 (2007) 1092-1100
52. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., and Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7 (2001) 186-191
53. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., and Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 (2001) 192-198
54. Auguste P., Lemiere S., Larrieu-Lahargue F., and Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit. Rev. Oncol. Hematol. 54 (2005) 53-61
55. Huber M.A., Kraut N., and Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17 (2005) 548-558
56. Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anat. (Basel) 154 (1995) 8-20
57. Stoker M., and Perryman M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 77 (1985) 209-223
58. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15 (2003) 740-746
59. Vincent-Salomon A., and Thiery J.P. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 5 (2003) 101-106
60. Weinberg R.A. The Biology of Cancer (2004), Garland Science, Taylor & Francis Group, New York
61. Bryden A.A., Freemont A.J., Clarke N.W., and George N.J. Paradoxical expression of E-cadherin in prostatic bone metastases. BJU Int. 84 (1999) 1032-1034
62. Bukholm I.K., Nesland J.M., and Borresen-Dale A.L. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [see comments]. J. Pathol. 190 (2000) 15-19
63. Park D., Karesen R., Axcrona U., Noren T., and Sauer T. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. APMIS 115 (2007) 52-65
64. Barker N., and Clevers H. Tumor environment: a potent driving force in colorectal cancer?. Trends Mol. Med. 7 (2001) 535-537
65. Brabletz T., Jung A., Spaderna S., Hlubek F., and Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5 (2005) 744-749
66. Muller T., Bain G., Wang X., and Papkoff J. Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Exp. Cell Res. 280 (2002) 119-133
67. Morali O.G., Delmas V., Moore R., Jeanney C., Thiery J.P., and Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20 (2001) 4942-4950
68. Thiery J.P., and Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7 (2006) 131-142
69. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., Clezardin P., and Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114 (2004) 1714-1725
70. Boucharaba A., Serre C.M., Guglielmi J., Bordet J.C., Clezardin P., and Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA 20 103 (2006) 9643-9648
71. Nieswandt B., Hafner M., Echtenacher B., and Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59 (1999) 1295-1300
72. Karpatkin S., Pearlstein E., Salk P.L., and Yogeeswaran G. Role of platelets in tumor cell metastases. Ann. N. Y. Acad. Sci. 370 (1981) 101-118
73. Trikha M., Zhou Z., Timar J., Raso E., Kennel M., Emmell E., and Nakada M.T. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62 (2002) 2824-2833
74. Batson O.V. The function of the vertebral veins and their role in the spread of metastasis. Ann. Surg. 112 (1940) 138-149
75. Ibukuro K., Fukuda H., Mori K., and Inoue Y. Topographic anatomy of the vertebral venous system in the thoracic inlet. AJR Am. J. Roentgenol. 176 (2001) 1059-1065
76. Coman D.R., and deLong R.P. The role of the vertebral venous system in the metastasis of cancer to the spinal column; experiments with tumor-cell suspensions in rats and rabbits. Cancer 4 (1951) 610-618
77. Baron R. Anatomy and ultrastructure of bone. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases an Disorders of Mineral Metabolism (1999), Lippincott Williams & Wilkins, Philadelphia 3-10
78. Erlebacher A., Filvaroff E.H., Gitelman S.E., and Derynck R. Toward a molecular understanding of skeletal development. Cell 80 (1995) 371-378
79. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
80. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am. J. Pathol. 170 (2007) 427-435
81. Marks Jr. S.C., and Lane P.W. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J. Heredity 67 (1976) 11-18
82. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L.D., and Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 (1990) 442-444
83. Felix R., Cecchini M.G., Hofstetter W., Elford P.R., Stutzer A., and Fleisch H. Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J. Bone Miner. Res. 5 (1990) 781-789
84. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., and Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96 (1999) 3540-3545
85. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
86. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., and Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253 (1998) 395-400
87. Tsukii K., Shima N., Mochizuki S., Yamaguchi K., Kinosaki M., Yano K., Shibata O., Udagawa N., Yasuda H., Suda T., and Higashio K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 19 246 (1998) 337-341
88. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
89. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15 (2004) 457-475
90. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
91. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
92. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., and Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
93. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
94. Lian J.B., Gary S., Stein G.S., Cancelas J.A., Robey P.G., and Boskey A.L. Bone formation: osteoblasts lineage cells, growth factors, matrix proteins, and the mineralization process. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases an Disorders of Mineral Metabolism (1999), Lippincott Williams & Wilkins, Philadelphia 14-29
95. Aubin J.E. Bone stem cells. J. Cell. Biochem. Suppl. 30-31 (1998) 73-82
96. Lian J.B., and Stein G.S. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr. Pharm. Des. 9 (2003) 2677-2685
97. Ducy P., Zhang R., Geoffroy V., Ridall A.L., and Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 (1997) 747-754
98. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., and Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 (1997) 755-764
99. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., and Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 (1997) 765-771
100. Korchynskyi O., van Bezooijen R.L., Löwik C.W.G.M., and Ten Dijke P. Bone morphogenetic protein receptors and nuclear effectors in bone formation. In: Vukicevic S., and Sampath K.T. (Eds). Bone Morphogenetic Proteins: Regeneration of Bone and Beyond (2004), Birkhäuser, Basel 9-44
101. van der Horst G., van Bezooijen R.L., Deckers M.M., Hoogendam J., Visser A., Lowik C.W., and Karperien M. Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation. Bone 31 (2002) 661-669
102. van der Horst G., Farih-Sips H., Lowik C.W., and Karperien M. Hedgehog stimulates only osteoblastic differentiation of undifferentiated KS483 cells. Bone 33 (2003) 899-910
103. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., Hartmann C., Li L., Hwang T.H., Brayton C.F., Lang R.A., Karsenty G., and Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157 (2002) 303-314
104. Knothe Tate M.L., Adamson J.R., Tami A.E., and Bauer T.W. The osteocyte. Int. J. Biochem. Cell Biol. 36 (2004) 1-8
105. Robey P.G., Fedarko N.S., Hefferan T.E., Bianco P., Vetter U.K., Grzesik W., Friedenstein A., van der P.G., Mintz K.P., and Young M.F. Structure and molecular regulation of bone matrix proteins. J. Bone Miner. Res. 8 Suppl 2 (1993) S483-S487
106. van der Pluijm G., Vloedgraven H.J., Ivanov B., Robey F.A., Grzesik W.J., Robey P.G., Papapoulos S.E., and Lowik C.W. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res. 56 (1996) 1948-1955
107. van der Pluijm G., Vloedgraven H., Papapoulos S., Lowick C., Grzesik W., Kerr J., and Robey P.G. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab. Invest. 77 (1997) 665-675
108. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., and Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem. 261 (1986) 12665-12674
109. Pietrzak W.S., Woodell-May J., and McDonald N. Assay of bone morphogenetic protein-2, -4, and -7 in human demineralized bone matrix. J. Craniofac. Surg. 17 (2006) 84-90
110. Pfeilschifter J., and Mundy G.R. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84 (1987) 2024-2028
111. Cecchini M.G., Wetterwald A., van der Pluijm G., and Thalmann G.N. Molecular and biological mechanisms of bone metastasis. EAU Upd. Ser. 3 (2005) 214-226
112. Frost H.M. Bone Biodynamics (1964), Little Brown, Boston
113. Mundy G.R. Bone remodeling. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (1999), Lippincott Williams & Wilkins, Philadelphia 30-38
114. Seeman E., and Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354 (2006) 2250-2261
115. Dallas S.L., Rosser J.L., Mundy G.R., and Bonewald L.F. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277 (2002) 21352-21360
116. Ross M.H., Romrell L.J., and Kaye G.I. Histology, A Text and Atlas. third ed. (1995), Williams & Wilkinson
117. Rizo A., Vellenga E., de Haan G., and Schuringa J.J. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?. Hum. Mol. Genet. 15 Spec No 2 (2006) R210-R219
118. Taichman R.S. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105 (2005) 2631-2639
119. Yin T., and Li L. The stem cell niches in bone. J. Clin. Invest. 116 (2006) 1195-1201
120. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., and Scadden D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
121. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., Ross J., Haug J., Johnson T., Feng J.Q., Harris S., Wiedemann L.M., Mishina Y., and Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
122. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., and Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283 (1999) 845-848
123. Cancelas J.A., Lee A.W., Prabhakar R., Stringer K.F., Zheng Y., and Williams D.A. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat. Med. 11 (2005) 886-891
124. Mohle R., Bautz F., Denzlinger C., and Kanz L. Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors. Ann N. Y. Acad. Sci. 938 discussion 34-5 (2001) 26-34
125. Katayama Y., Hidalgo A., Furie B.C., Vestweber D., Furie B., and Frenette P.S. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood 102 (2003) 2060-2067
126. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
127. Garlanda C., and Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1193-1202
128. Dimitroff C.J., Descheny L., Trujillo N., Kim R., Nguyen V., Huang W., Pienta K.J., Kutok J.L., and Rubin M.A. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res. 65 (2005) 5750-5760
129. Dimitroff C.J., Lechpammer M., Long-Woodward D., and Kutok J.L. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res. 64 (2004) 5261-5269
130. Sipkins D.A., Wei X., Wu J.W., Runnels J.M., Cote D., Means T.K., Luster A.D., Scadden D.T., and Lin C.P. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435 (2005) 969-973
131. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
132. Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Wang J., Cook K., Osman N.I., Koh-Paige A.J., Shim H., Pienta K.J., Keller E.T., McCauley L.K., and Taichman R.S. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 20 (2005) 318-329
133. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., and McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62 (2002) 1832-1837
134. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5 (2004) 816-826
135. Sun Y.X., Fang M., Wang J., Cooper C.R., Pienta K.J., and Taichman R.S. Expression and activation of alpha(v)beta(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67 (2007) 61-73
136. Harms J.F., Welch D.R., Samant R.S., Shevde L.A., Miele M.E., Babu G.R., Goldberg S.F., Gilman V.R., Sosnowski D.M., Campo D.A., Gay C.V., Budgeon L.R., Mercer R., Jewell J., Mastro A.M., Donahue H.J., Erin N., Debies M.T., Meehan W.J., Jones A.L., Mbalaviele G., Nickols A., Christensen N.D., Melly R., Beck L.N., Kent J., Rader R.K., Kotyk J.J., Pagel M.D., Westlin W.F., and Griggs D.W. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21 (2004) 119-128
137. Zhao Y., Bachelier R., Treilleux I., Pujuguet P., Peyruchaud O., Baron R., Clement-Lacroix P., and Clezardin P. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 67 (2007) 5821-5830
138. McCabe N.P., De S., Vasanji A., Brainard J., and Byzova T.V. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 26 (2007) 6238-6243
139. Pecheur I., Peyruchaud O., Serre C.M., Guglielmi J., Voland C., Bourre F., Margue C., Cohen-Solal M., Buffet A., Kieffer N., and Clezardin P. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 16 (2002) 1266-1268
140. Sloan E.K., Pouliot N., Stanley K.L., Chia J., Moseley J.M., Hards D.K., and Anderson R.L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8 (2006) R20
141. Karadag A., Ogbureke K.U., Fedarko N.S., and Fisher L.W. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst. 96 (2004) 956-965
142. Rolli M., Fransvea E., Pilch J., Saven A., and Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 9482-9487
143. Hill A., McFarlane S., Johnston P.G., and Waugh D.J. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 237 (2006) 1-9
144. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., Ratajczak J., and Ratajczak M.Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 (2005) 879-894
145. Bellahcene A., and Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 146 (1995) 95-100
146. Bellahcene A., Kroll M., Liebens F., and Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res. 11 (1996) 665-670
147. Knerr K., Ackermann K., Neidhart T., and Pyerin W. Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int. J. Cancer 111 (2004) 152-159
148. Koeneman K.S., Yeung F., and Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 (1999) 246-261
149. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
150. Kaplan R.N., Rafii S., and Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 66 (2006) 11089-11093
151. Arguello F., Baggs R.B., Graves B.T., Harwell S.E., Cohen H.J., and Frantz C.N. Effect of IL-1 on experimental bone/bone-marrow metastases. Int. J. Cancer 52 (1992) 802-807
152. Kostenuik P.J., Singh G., Suyama K.L., and Orr F.W. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin. Exp. Metastasis 10 (1992) 411-418
153. Schneider A., Kalikin L.M., Mattos A.C., Keller E.T., Allen M.J., Pienta K.J., and McCauley L.K. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146 (2005) 1727-1736
154. Brown J.E., Thomson C.S., Ellis S.P., Gutcher S.A., Purohit O.P., and Coleman R.E. Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer 89 (2003) 2031-2037
155. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., Smith M., Lee K.A., Zheng M., Hei Y.J., and Coleman R.E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97 (2005) 59-69
156. Costa L., Demers L.M., Gouveia-Oliveira A., Schaller J., Costa E.B., de Moura M.C., and Lipton A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 20 (2002) 850-856
157. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat. Rev. 27 (2001) 187-192
158. Coleman R.E. Bisphosphonates in breast cancer. Ann. Oncol. 16 (2005) 687-695
159. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 4 (2002) 30-34
160. Michaelson M.D., and Smith M.R. Bisphosphonates for treatment and prevention of bone metastases. J. Clin. Oncol. 23 (2005) 8219-8224
161. Body J.J., Diel I.J., Lichinitser M.R., Kreuser E.D., Dornoff W., Gorbunova V.A., Budde M., and Bergstrom B. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14 (2003) 1399-1405
162. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., Reitsma D.J., Heffernan M., and Seaman J.J. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
163. Powles T., Paterson A., McCloskey E., Schein P., Scheffler B., Tidy A., Ashley S., Smith I., Ottestad L., and Kanis J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 8 (2006) R13
164. Rosen L.S., Gordon D.H., Dugan Jr. W., Major P., Eisenberg P.D., Provencher L., Kaminski M., Simeone J., Seaman J., Chen B.L., and Coleman R.E. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 (2004) 36-43
165. Kanis J.A., Powles T., Paterson A.H., McCloskey E.V., and Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19 (1996) 663-667
166. Conte P.F., Latreille J., Mauriac L., Calabresi F., Santos R., Campos D., Bonneterre J., Francini G., and Ford J.M. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J. Clin. Oncol. 14 (1996) 2552-2559
167. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., and Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339 (1998) 357-363
168. van Holten-Verzantvoort A.T., Hermans J., Beex L.V., Blijham G., Cleton F.J., Eck-Smit B.C., Sleeboom H.P., and Papapoulos S.E. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?. Eur. J. Cancer 32A (1996) 450-454
169. Saarto T., Vehmanen L., Virkkunen P., and Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43 (2004) 650-656
170. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., and Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61 (2001) 4432-4436
171. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., Holloway D., Peterson M.C., and Bekker P.J. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12 (2006) 1221-1228
172. Le Gall C., Bellahcene A., Bonnelye E., Gasser J.A., Castronovo V., Green J., Zimmermann J., and Clezardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67 (2007) 9894-9902
173. Blair J.M., Zhou H., Seibel M.J., and Dunstan C.R. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 3 (2006) 41-49
174. Clohisy D.R., and Ramnaraine M.L. Osteoclasts are required for bone tumors to grow and destroy bone. J. Orthop. Res. 16 (1998) 660-666
175. Kakonen S.M., and Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 (2003) 834-839
176. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., and Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 (1999) 4451-4458
177. Southby J., Kissin M.W., Danks J.A., Hayman J.A., Moseley J.M., Henderson M.A., Bennett R.C., and Martin T.J. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 50 (1990) 7710-7716
178. Iddon J., Bundred N.J., Hoyland J., Downey S.E., Baird P., Salter D., McMahon R., and Freemont A.J. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J. Pathol. 191 (2000) 170-174
179. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., Yoneda T., and Mundy G.R. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98 (1996) 1544-1549
180. Powell G.J., Southby J., Danks J.A., Stillwell R.G., Hayman J.A., Henderson M.A., Bennett R.C., and Martin T.J. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 51 (1991) 3059-3061
181. Kissin M.W., Henderson M.A., Danks J.A., Hayman J.A., Bennett R.C., and Martin T.J. Parathyroid hormone related protein in breast cancers of widely varying prognosis. Eur. J. Surg. Oncol. 19 (1993) 134-142
182. Bundred N.J., Walker R.A., Ratcliffe W.A., Warwick J., Morrison J.M., and Ratcliffe J.G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur. J. Cancer 28 (1992) 690-692
183. Henderson M., Danks J., Moseley J., Slavin J., Harris T., McKinlay M., Hopper J., and Martin T. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J. Natl. Cancer Inst. 93 (2001) 234-237
184. Henderson M.A., Danks J.A., Slavin J.L., Byrnes G.B., Choong P.F., Spillane J.B., Hopper J.L., and Martin T.J. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 66 (2006) 2250-2256
185. Kohno N., Kitazawa S., Sakoda Y., Kanbara Y., Furuya Y., Ohashi O., and Kitazawa R. Parathyroid hormone-related protein in breast cancer tissues: relationship between primary and metastatic sites. Breast Cancer 1 (1994) 43-49
186. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., Massague J., Mundy G.R., and Guise T.A. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103 (1999) 197-206
187. Buijs J.T., Henriquez N.V., van Overveld P.G., van der H.G., Que I., Schwaninger R., Rentsch C., Ten Dijke P., Cleton-Jansen A.M., Driouch K., Lidereau R., Bachelier R., Vukicevic S., Clezardin P., Papapoulos S.E., Cecchini M.G., Lowik C.W., and van der P.G. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 67 (2007) 8742-8751
188. Buijs J.T., Rentsch C.A., van der Horst G., van Overveld P.G.M., Wetterwald A., Schwaninger R., Henriquez N.V., Ten Dijke P., Borovecki F., Markwalder R., Thalmann G.N., Papapoulos S.E., Pelger R.C.M., Vukicevic S., Cecchini M.G., Löwik C.W.G.M., and van der Pluijm G. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am. J. Pathol. 171 (2007) 1047-1057
189. Virk M.S., and Lieberman J.R. Tumor metastasis to bone. Arthritis Res. Ther. 9 Suppl 1 (2007) S5
190. Bendre M.S., Montague D.C., Peery T., Akel N.S., Gaddy D., and Suva L.J. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33 (2003) 28-37
191. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., Gu K., Shah V., Pei L., Zarbo R.J., McCauley L., Shi S., Chen S., and Wang C.Y. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 13 (2007) 62-69
192. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., Saad F., Zheng M., Hei Y.J., Seaman J., and Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23 (2005) 4925-4935
193. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., and Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urol. 157 (1997) 539-543
194. Urist M.R. Bone: formation by autoinduction. Science 150 (1965) 893-899
195. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., and Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 242 (1988) 1528-1534
196. Ye L., Lewis-Russell J.M., Kyanaston H.G., and Jiang W.G. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol. Histopathol. 22 (2007) 1129-1147
197. Dai J., Kitagawa Y., Zhang J., Yao Z., Mizokami A., Cheng S., Nor J., McCauley L.K., Taichman R.S., and Keller E.T. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 64 (2004) 994-999
198. Feeley B.T., Gamradt S.C., Hsu W.K., Liu N., Krenek L., Robbins P., Huard J., and Lieberman J.R. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J. Bone Miner. Res. 20 (2005) 2189-2199
199. Schwaninger R., Rentsch C.A., Wetterwald A., van der H.G., van Bezooijen R.L., van der P.G., Lowik C.W., Ackermann K., Pyerin W., Hamdy F.C., Thalmann G.N., and Cecchini M.G. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am. J. Pathol. 170 (2007) 160-175
200. Dai J., Keller J., Zhang J., Lu Y., Yao Z., and Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 65 (2005) 8274-8285
201. Hall C.L., Kang S., MacDougald O.A., and Keller E.T. Role of Wnts in prostate cancer bone metastases. J. Cell. Biochem. 97 (2006) 661-672
202. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., and Shaughnessy Jr. J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349 (2003) 2483-2494
203. Voorzanger-Rousselot N., Goehrig D., Journe F., Doriath V., Body J.J., Clezardin P., and Garnero P. Increased dickkopf-1 expression in breast cancer bone metastases. Br. J. Cancer 97 (2007) 964-970
204. Logothetis C.J., and Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5 (2005) 21-28
205. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., and Simons J.W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1 (1995) 944-949
206. Nelson J.B., Nguyen S.H., Wu-Wong J.R., Opgenorth T.J., Dixon D.B., Chung L.W., and Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53 (1999) 1063-1069
207. Yuyama H., Koakutsu A., Fujiyasu N., Tanahashi M., Fujimori A., Sato S., Shibasaki K., Tanaka S., Sudoh K., Sasamata M., and Miyata K. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur. J. Pharmacol. 492 (2004) 177-182
208. Banerjee S., Hussain M., Wang Z., Saliganan A., Che M., Bonfil D., Cher M., and Sarkar F.H. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67 (2007) 3818-3826
209. Yin J.J., Mohammad K.S., Kakonen S.M., Harris S., Wu-Wong J.R., Wessale J.L., Padley R.J., Garrett I.R., Chirgwin J.M., and Guise T.A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA 100 (2003) 10954-10959
210. Carducci M.A., and Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin. Cancer Res. 12 (2006) 6296s-6300s
211. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., Daliani D.D., Schulman C.C., Nabulsi A.A., Humerickhouse R.A., Weinberg M.A., Schmitt J.L., and Nelson J.B. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J. Clin. Oncol. 21 (2003) 679-689
212. Cella D., Petrylak D.P., Fishman M., Teigland C., Young J., and Mulani P. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?. Eur. Urol. 49 (2006) 781-789
213. Rabbani S.A., Desjardins J., Bell A.W., Banville D., Mazar A., Henkin J., and Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. Commun. 173 (1990) 1058-1064
214. Cohen P., Peehl D.M., Graves H.C., and Rosenfeld R.G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol. 142 (1994) 407-415
215. Cramer S.D., Chen Z., and Peehl D.M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156 (1996) 526-531
216. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., and Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
217. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R., and Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115 (2005) 44-55
218. Smid M., Wang Y., Klijn J.G., Sieuwerts A.M., Zhang Y., Atkins D., Martens J.W., and Foekens J.A. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24 (2006) 2261-2267